Prelude Stock Surges: Phio's PH-762 Shines in Trials!

viernes, 6 de junio de 2025, 4:00 pm ET1 min de lectura
PHIO--
PRLD--
Prelude Therapeutics Incorporated rose 5.32% intraday, with recent news from Phio Pharmaceuticals Corp.PHIO-- (NASDAQ: PHIO) potentially influencing the market sentiment. Phio PharmaceuticalsPHIO-- announced a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds. Additionally, positive interim safety and efficacy results were reported in the ongoing Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios